Disease progression in C9orf72 mutation carriers

被引:32
|
作者
Floeter, Mary K. [1 ]
Traynor, Bryan J. [2 ]
Farren, Jennifer [1 ]
Braun, Laura E. [1 ]
Tierney, Michael [1 ]
Wiggs, Edythe A. [1 ]
Wu, Tianxia [1 ]
机构
[1] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA
[2] NIA, NIH, Bethesda, MD 20892 USA
关键词
AMYOTROPHIC-LATERAL-SCLEROSIS; FRONTOTEMPORAL DEMENTIA; BEHAVIORAL VARIANT; REPEAT EXPANSION; HEXANUCLEOTIDE REPEAT; CLINICAL-TRIALS; RATING-SCALE; ALS; COGNITION; DECLINE;
D O I
10.1212/WNL.0000000000004115
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To assess changes in 3 clinical measures, the Revised ALS Functional Rating Scale (ALSFRS-R), letter fluency, and Frontal Behavioral Inventory (FBI), over time in C9orf72 mutation carriers (C9+) with varied clinical phenotypes. Methods: Thirty-four unrelated participants with mutations in C9orf72 were enrolled in a prospective natural history study. Participants were classified as asymptomatic, amyotrophic lateral sclerosis (ALS), ALS-familial frontotemporal dementia (FTD), or behavioral-variant FTD by clinical diagnostic criteria. Diagnostic cognitive and motor tests were repeated at 6 and 18 months. The ALSFRS-R, letter fluency, and FBI were administered at baseline and follow-up visits at 6, 12, and 18 months. Results: The clinical diagnosis of most patients did not change over the follow-up. ALSFRS-R scores correlated with measures of motor function. Letter fluency correlated with FBI and cognitive tests. ALSFRS-R, letter fluency, and FBI differed among the C9+ diagnostic subgroups at enrollment and worsened over follow-up in symptomatic patients, with different slopes among the subgroups. Most patients survived to the 6-month time point after enrollment. Survival of C9+ patients with ALS and C9+ patients with ALS-FTD declined over the 12- and 18-month follow-up. Conclusions: The pattern of scores of the ALSFRS-R, letter fluency, and FBI distinguished between ALS, ALS-FTD, and FTD presentations of C9orf72 mutation carriers and asymptomatic carriers. Longitudinal changes in these measures occurred with disease progression in a manner consistent with presenting phenotype.
引用
收藏
页码:234 / 241
页数:8
相关论文
共 50 条
  • [21] C9ORF72 Mutations in Neurodegenerative Diseases
    Liu, Ying
    Yu, Jin-Tai
    Zong, Yu
    Zhou, Jing
    Tan, Lan
    MOLECULAR NEUROBIOLOGY, 2014, 49 (01) : 386 - 398
  • [22] Jump from Pre-mutation to Pathologic Expansion in C9orf72
    Xi, Zhengrui
    van Blitterswijk, Marka
    Zhang, Ming
    McGoldrick, Philip
    McLean, Jesse R.
    Yunusova, Yana
    Knock, Erin
    Moreno, Danielle
    Sato, Christine
    McKeever, Paul M.
    Schneider, Raphael
    Keith, Julia
    Petrescu, Nicolae
    Fraser, Paul
    Tartaglia, Maria Carmela
    Baker, Matthew C.
    Graff-Radford, Neill R.
    Boylan, Kevin B.
    Dickson, Dennis W.
    Mackenzie, Ian R.
    Rademakers, Rosa
    Robertson, Janice
    Zinman, Lorne
    Rogaeva, Ekaterina
    AMERICAN JOURNAL OF HUMAN GENETICS, 2015, 96 (06) : 962 - 970
  • [23] Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers
    Gendron, Tania F.
    van Blitterswijk, Marka
    Bieniek, Kevin F.
    Daughrity, Lillian M.
    Jiang, Jie
    Rush, Beth K.
    Pedraza, Otto
    Lucas, John A.
    Murray, Melissa E.
    Desaro, Pamela
    Robertson, Amelia
    Overstreet, Karen
    Thomas, Colleen S.
    Crook, Julia E.
    Castanedes-Casey, Monica
    Rousseau, Linda
    Josephs, Keith A.
    Parisi, Joseph E.
    Knopman, David S.
    Petersen, Ronald C.
    Boeve, Bradley F.
    Graff-Radford, Neill R.
    Rademakers, Rosa
    Lagier-Tourenne, Clotilde
    Edbauer, Dieter
    Cleveland, Don W.
    Dickson, Dennis W.
    Petrucelli, Leonard
    Boylan, Kevin B.
    ACTA NEUROPATHOLOGICA, 2015, 130 (04) : 559 - 573
  • [24] Heterogeneous brain FDG-PET metabolic patterns in patients with C9orf72 mutation
    Castelnovo, Veronica
    Caminiti, Silvia Paola
    Riva, Nilo
    Magnani, Giuseppe
    Silani, Vincenzo
    Perani, Daniela
    NEUROLOGICAL SCIENCES, 2019, 40 (03) : 515 - 521
  • [25] RANTing about C9orf72
    Lashley, Tammaryn
    Hardy, John
    Isaacs, Adrian M.
    NEURON, 2013, 77 (04) : 597 - 598
  • [26] Psychopathology in premanifest C9orf72 repeat expansion carriers
    De Vocht, Joke
    Stam, Daphne
    Nicolini, Marie
    Lamaire, Nikita
    Laroy, Maarten
    Vande Casteele, Thomas
    van de Vliet, Laura
    Vansteelandt, Kristof
    D'Hondt, Ann
    Emsell, Louise
    Bruffaerts, Ronny
    Vandenbulcke, Mathieu
    van Damme, Philip
    van den Stock, Jan
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (05) : 565 - 567
  • [27] The C9ORF72 mutation brings more answers and more questions
    Miller, Bruce L.
    ALZHEIMERS RESEARCH & THERAPY, 2013, 5 (01):
  • [28] Electrical impedance myography (EIM) in a natural history study of C9ORF72 mutation carriers
    Offit, Michelle B.
    Wu, Tianxia
    Floeter, Mary Kay
    Lehky, Tanya J.
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2020, 21 (5-6) : 445 - 451
  • [29] Eye movement alterations in presymptomatic C9orf72 expansion gene carriers
    Behler, Anna
    Knehr, Antje
    Finsel, Julia
    Kunz, Martin S.
    Lang, Christina
    Mueller, Kathrin
    Mueller, Hans-Peter
    Pinkhardt, Elmar H.
    Ludolph, Albert C.
    Lule, Dorothee
    Kassubek, Jan
    JOURNAL OF NEUROLOGY, 2021, 268 (09) : 3390 - 3399
  • [30] A small deletion in C9orf72 hides a proportion of expansion carriers in FTLD
    Rollinson, Sara
    Callister, Janis Bennion
    Young, Kate
    Ryan, Sarah J.
    Druyeh, Ronald
    Rohrer, Jonathan D.
    Snowden, Julie
    Richardson, Anna
    Jones, Matt
    Harris, Jenny
    Davidson, Yvonne
    Robinson, Andrew
    Ealing, John
    Johnson, Janel O.
    Traynor, Bryan
    Mead, Simon
    Mann, David
    Pickering-Brown, Stuart M.
    NEUROBIOLOGY OF AGING, 2015, 36 (03) : 1601.e1 - e5